Astemizole
Title: Astemizole
CAS Registry Number: 68844-77-9
CAS Name: 1-[(4-Fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazol-2-amine
Additional Names: 1-(p-fluorobenzyl)-2-[[1-(p-methoxyphenethyl)-4-piperidyl]amino]benzimidazole
Manufacturers' Codes: R-43512
Trademarks: Astemisan (Zdravlje); Hismanal (Janssen); Histamen (Polifarma); Histaminos (Lesvi); Kelp (Omni); Laridal (Elfar-Drag); Metodik (Labinca); Novo-Nastizol A (Bago); Paralergin (Vita); Retolen (Byk Elmu); Waruzol (Farmanic)
Molecular Formula: C28H31FN4O
Molecular Weight: 458.57
Percent Composition: C 73.34%, H 6.81%, F 4.14%, N 12.22%, O 3.49%
Literature References: Nonsedating-type histamine H1-receptor antagonist. Prepn: F. Janssens et al., EP 5318; eidem, US 4219559 (1979, 1980 both to Janssen). Pharmacology: J. Van Wauwe et al., Arch. Int. Pharmacodyn. Ther. 251, 39 (1981); A. Wauquier, C. J. E. Niemegeers, Eur. J. Pharmacol. 72, 245 (1981). In vitro and in vivo binding characteristics: P. M. Laduron et al., Mol. Pharmacol. 21, 294 (1982). Effect on human psychomotor performance: T. Seppala, K. Savolainen, Curr. Ther. Res. 31, 638 (1982). Clinical study in treatment of hay fever: J. Callier et al., ibid. 29, 24 (1981). Mutagenicity study: P. Vanparys et al., Arch. Toxicol. 50, 167 (1982). Review of pharmacology and clinical trials: D. M. Richards et al., Drugs 28, 38-61 (1984). Comprehensive description: A. M. Al-Obaid, M. S. Mian, Anal. Profiles Drug Subs. 20, 173-208 (1991).
Properties: Crystals from 2,2¢-oxybispropane, mp 172.9°. Freely sol in organic solvents. Practically insol in water. uv max (ethanol): 219, 249, 286 nm (e 27250.229, 6480.293, 8634.280); (0.1N HCl): 209, 277 nm (e 57889.908, 18073.394).
Melting point: mp 172.9°
Absorption maximum: uv max (ethanol): 219, 249, 286 nm (e 27250.229, 6480.293, 8634.280)
Therap-Cat: Antihistaminic.
Keywords: Antihistaminic.

Others monographs:
HassiumMethaphenileneMagnesium SulfiteHexacyclonate Sodium
RhizoxinScillarenCobaltous HydroxideNolatrexed
GlyceraldehydePerflubronPivcefalexinNodulisporic acid
PyridofyllinePropamidineBarium Uranium OxideJulocrotine
©2016 DrugLead US FDA&EMEA